George Le-Bert, DO
Cardiovascular Disease · Fernandina Beach, FLNPI 1033318928
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 676 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 9.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,524, 2.2 times the $1,592 reported in 2019.
Across 676 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Novartis$1K
- Boehringer Ingelheim$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$983
- Pfizer$902
- AstraZeneca$878
- plus $9K from 31 others
Across 9 payments — averaging $1646.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15K
What the payments were for
- Food & beverage$15,27997%
- Education$4803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 61 | $1,440 |
| Novartis | 61 | $1,150 |
| Boehringer Ingelheim | 47 | $1,141 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 36 | $983 |
| Pfizer | 45 | $902 |
| AstraZeneca | 37 | $878 |
| Merck | 41 | $806 |
| Bayer | 43 | $802 |
| Amgen | 45 | $765 |
| Sanofi-aventis U.S. LLC | 28 | $674 |
| Alnylam Pharmaceuticals Inc. | 25 | $664 |
| Novo Nordisk | 24 | $627 |
| Cvrx, Inc. | 24 | $605 |
| E.r. Squibb & Sons, L.L.C. | 36 | $592 |
| Abbott | 6 | $513 |
| Esperion Therapeutics, Inc. | 29 | $507 |
| Amarin Pharma, Inc. | 10 | $414 |
| Irhythm Technologies, Inc. | 11 | $342 |
| Scpharmaceuticals Inc. | 5 | $232 |
| Bridgebio Pharma, Inc. | 5 | $221 |
| United Therapeutics Corporation | 5 | $202 |
| Actelion Pharmaceuticals US, Inc. | 5 | $194 |
| Baxter Healthcare | 3 | $171 |
| Medtronic(2 entities) | 5 | $160 |
| Abiomed | 5 | $124 |
| Lexicon Pharmaceuticals, Inc. | 7 | $122 |
| Lundbeck LLC | 7 | $121 |
| Boston Scientific | 3 | $76 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $59 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $50 |
| Cordis US CORP. | 2 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Philips North America LLC | 1 | $37 |
| Kestra Medical Technology Services, Inc. | 1 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Sanofi | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$471
- Vascepa$278
- JARDIANCE$228
- LifeVest$210
- MitraClip$166
- AMPLATZER Occluders$158
- ZIO XT Patch$151
- Zio monitor$151
- Attruby$150
- Hillrom - Carnation Ambulatory Monitor$143
- FUROSCIX$138
- AMVUTTRA$132
- MitraClip System$123
- Repatha$109
- RYBELSUS$109
- COBALT DR MRI SURESCAN$100
How this compares
$15,758 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 42 | $1,393,406 |
| EliquisApixaban | 762 | $912,243 |
| XareltoRivaroxaban | 260 | $351,534 |
| Repatha SureclickEvolocumab | 354 | $256,987 |
| VascepaIcosapent Ethyl | 282 | $244,753 |
| EntrestoSacubitril/Valsartan | 141 | $188,279 |
| JardianceEmpagliflozin | 149 | $184,215 |
| CamzyosMavacamten | 20 | $162,679 |
| Repatha PushtronexEvolocumab | 191 | $140,872 |
| MultaqDronedarone Hcl | 88 | $138,870 |
| FarxigaDapagliflozin Propanediol | 125 | $125,921 |
| Praluent PenAlirocumab | 91 | $56,129 |
| NexlizetBempedoic Acid/Ezetimibe | 36 | $32,699 |
| LivaloPitavastatin Calcium | 19 | $18,505 |
| OzempicSemaglutide | 16 | $15,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $902 | $2,305,649804 claims |
| Johnson & JohnsonXarelto | $1,440 | $351,534260 claims |
| NovartisEntresto | $1,150 | $188,279141 claims |
| Boehringer IngelheimJardiance | $1,141 | $184,215149 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $592 | $162,67920 claims |
| Sanofi-aventis U.S. LLCMultaq | $674 | $138,87088 claims |
| AstraZenecaFarxiga, Brilinta | $878 | $131,803137 claims |
| Esperion Therapeutics, Inc.Nexlizet | $507 | $32,69936 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $38 | $18,50519 claims |
| Novo NordiskOzempic | $627 | $15,37916 claims |
| BayerKerendia | $802 | $11,79014 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $28 | $7,03022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Fernandina Beach
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.